Glioblastoma multiforme: enhancing survival and quality of life.

22:20 EST 20th December 2014 | BioPortfolio

Summary of "Glioblastoma multiforme: enhancing survival and quality of life."

A diagnosis of a malignant brain tumor is devastating to patients and their families. The patients' inevitable loss of independence, which can occur suddenly or gradually, is tragic, and the eventual complete dependence can be overwhelming to the family and caregivers. Glioblastoma multiforme (GBM) is the most common type of primary malignant brain tumor in adults and is associated with a disproportionately high mortality rate. The highly malignant tumor grows rapidly and has a tendency to recur through treatment. The brain itself presents a multitude of barriers to treatment, such as tumor location, accessibility for surgery, and the blood-brain barrier's natural protection. Despite access to optimal multimodality treatment, patients diagnosed with GBM have a low survival rate. Patients and families need emotional and practical support throughout the continuum of this devastating disease. Astute neurologic assessment skills and immediate and appropriate interventions are required to maintain the patient's functional status. This article provides an overview of the treatment of GBM and reviews how oncology nurses can intervene to positively improve the quality of life of patients and their families.

Affiliation

Department of Ambulatory Nursing, Memorial Sloan-Kettering Cancer Center, New York, NY.

Journal Details

This article was published in the following journal.

Name: Clinical journal of oncology nursing
ISSN: 1538-067X
Pages: 291-7

Links

PubMed Articles [18164 Associated PubMed Articles listed on BioPortfolio]

Bevacizumab as Secondline Treatment of Glioblastoma -  Worth the Effort?

Objective: To evaluate the role of bevacizumab and irinotecan as secondline treatment of glioblastoma in patients with progression after radiotherapy and temozolomide. Methods: A retrospective analysi...

Rare clinical form of glioblastoma multiforme.

Glioblastoma multiforme (glioblastoma multiforme - GBM) is the most malignant tumor classified by WHO. It is also the most common primary CNS tumor with a very aggressive course and unfavourable progn...

Impact of tumor infiltrating CD63 positive cells on survival in patients with glioblastoma multiforme.

Glioblastoma multiforme (GBM) is the most aggressive type of brain cancer in adults. It is suggested that tumour microenvironment might influence treatment outcome. The aim of the study was to evaluat...

Radiologically defined ecological dynamics and clinical outcomes in glioblastoma multiforme: preliminary results.

We examined pretreatment magnetic resonance imaging (MRI) examinations from 32 patients with glioblastoma multiforme (GBM) enrolled in The Cancer Genome Atlas (TCGA). Spatial variations in T1 post-gad...

Connection between Cell Phone use, p53 Gene Expression in Different Zones of Glioblastoma Multiforme and Survival Prognoses.

The aim of this paper is to investigate p53 gene expression in the central and peripheral zones of glioblastoma multiforme using a real-time reverse transcription polymerase chain reaction (RT-PCR) te...

Clinical Trials [4643 Associated Clinical Trials listed on BioPortfolio]

Radiation Boost for Newly Diagnosed Glioblastoma Multiforme

The purpose of this study is to determine treatment related toxicity, tumor response, progression-free survival and quality of life of newly diagnosed Glioblastoma Multiforme (GBM) patient...

Usefulness of Therapy Monitoring by Means of [(18)F]Fluoroethyltyrosine-Positron Emission Tomography (FET-PET) in Glioblastoma Multiforme Patients

The aim of this study is to establish FET-PET as an additional therapy assessment parameter in patients diagnosed with a glioblastoma multiforme receiving radiochemotherapy and adjuvant ch...

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Investigational study to assess the overall response (OR) rate (CR + PR) of Imatinib mesylate and Hydroxyurea (Hydroxycarbamide) combination therapy on patients with recurrent glioblastoma...

Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme

The purpose of this research study is to try and identify a more effective treatment plan to improve survival rates for patients with a recurrent Glioblastoma Multiforme (GBM) brain tumor ...

A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression

The purpose of this study is to find out whether the new drug PX-866 will slow the growth of your glioblastoma multiforme.

Medical and Biotech [MESH] Definitions

A measurement index derived from a modification of standard life-table procedures and designed to take account of the quality as well as the duration of survival. This index can be used in assessing the outcome of health care procedures or services. (BIOETHICS Thesaurus, 1994)

Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)

Continuance of life or existence especially under adverse conditions; includes methods and philosophy of survival.

A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral and social environment; the overall condition of a human life.

Persons who have experienced a prolonged survival after serious disease or who continue to live with a usually life-threatening condition as well as family members, significant others, or individuals surviving traumatic life events.

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Alzheimer's Disease
Latest News Clinical Trials Research Drugs Reports Corporate
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...

Advertisement